China Writing in the March 2022 edition of DIA’s Global Forum magazine, Jessie Zhu of Deltamed Co. Ltd./Pharmaron Clinical and Monica Juping Xu of Taimei Medical Technology outline the progress of pharmacovigilance standards in China, and make the call for greater levels of digitalisation and training.   Since China joined ICH…

Hong Kong Having consolidated its position as Asia’s largest biotech fundraising hub – and the world’s second largest – the Hong Kong Stock Exchange (HKEX) listed a total of 34 biotech and healthcare companies in 2021. “[Last year’s listings] made us rank first by number of deals and second by the amount…

China A selection of recent top stories from the Chinese pharma industry, including China’s conditional approval of Pfizer’s COVID treatment pill Paxlovid; a new push to combat monopoly practices and unfair competition in the domestic industry; and US FDA concerns about the applicability of Chinese clinical trial results for the US…

China PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of COVID-19 vaccines in China.   Since the breakout of COVID-19, many pharmaceutical companies in China have worked to develop preventative…

China Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s reimbursement list in 2021; the former GSK scientist pleading guilty to stealing trade secrets for Chinese pharma; and BioNTech’s continuing…

China The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and the significant price cuts that have been agreed. Also included are the World Health Organization (WHO)’s plea to Chinese COVID-19…

China The phenomenal success of the Pfizer/BioNTech and Moderna COVID-19 vaccines has catapulted messenger RNA (mRNA) vaccines into public consciousness, and mRNA technology is today receiving more scientific and financial attention than ever before. Suzhou, China-based biotech Abogen, for example, which has an mRNA-based COVID vaccine in late-stage development, has received…

China Perhaps Chinese biotech’s biggest success story, cancer-focused Beigene has evolved from the commitment of founders John Oyler and Xiaodong Wang to conducting clinical research in China with a global outlook. Fresh from recent announcements of an IPO in Shanghai to add to listings on NASDAQ and in Hong Kong and…

China Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China as of November 2021.   Since first joining the company back in 2002, Afonso held a variety of roles IT…

China The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval designations have been awarded since 2015. Elsewhere, Pfizer is utilising drone technology to promote health education in remote areas and…

China The latest news from Chinese pharma and biotech, including BMS’ attempts to pull out of its Abraxane supply deal with local player BeiGene; a conversation with Qihan Biotech CEO Luhan Yang who is aiming to produce the first pig organs that can be successfully transplanted into humans; and the Republican…

China The following is an overview from Accestra Consulting* of Part 2 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including an overview of administrative drug approvals and fast track review pathways by CDE.   Abstract Despite severe challenges from the COVID-19 pandemic, the Center for Drug Evaluation (CDE) of…